Lawmakers grill key FDA official over controversial Alzheimer’s drug approval

WASHINGTON — The Food and Drug Administration can’t escape questions about Aduhelm.

Patrizia Cavazzoni, one of the agency’s highest-ranking drug regulators, set out to testify before Congress Thursday on the intricacies of three looming funding bills crucial to the agency’s operations. But again and again, lawmakers grilled her about Biogen’s controversial Alzhiemer’s drug.

One lawmaker, Rep. Jan Schakowsky (D-Ill.), even joined the meeting just to chide Cavazzoni, even though she’s not a member of the subcommittee that held the hearing.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In